UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, Provides FY20 EPS Outlook
Go back to UPDATE: Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 3c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus, Provides FY20 EPS Outlook| AmerElite Solutions, Inc. New (NASDAQ: AMRX) | Delayed: 12.88 +0.23 (1.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.65 | 52 Week High | $0.19 | |||
| Open | $12.57 | 52 Week Low | $0.07 | |||
| Day High | $12.90 | P/E | N/A | |||
| Day Low | $12.49 | EPS | $-0.01 | |||
| Volume | 1,204,565 | |||||
